Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr83.50 SEK
Change Today -4.25 / -4.84%
Volume 5.5K
BOUL On Other Exchanges
Symbol
Exchange
Stockholm
As of 12:29 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

boule diagnostics internatio (BOUL) Snapshot

Open
kr87.00
Previous Close
kr87.75
Day High
kr87.00
Day Low
kr83.25
52 Week High
03/10/15 - kr94.00
52 Week Low
04/2/14 - kr40.00
Market Cap
393.0M
Average Volume 10 Days
5.8K
EPS TTM
kr6.44
Shares Outstanding
4.7M
EX-Date
05/13/15
P/E TM
13.0x
Dividend
kr0.60
Dividend Yield
0.60%
Current Stock Chart for BOULE DIAGNOSTICS INTERNATIO (BOUL)

Related News

No related news articles were found.

boule diagnostics internatio (BOUL) Related Businessweek News

No Related Businessweek News Found

boule diagnostics internatio (BOUL) Details

Boule Diagnostics AB, a diagnostics company, develops, manufactures, and markets complete blood count systems for the healthcare sector in Sweden and internationally. The company offers hematology systems, including reagents, calibrators, controls, analyzers, and accessories for the human and veterinary markets under the exigo, Medonic, Swelab, and Quintus brand names. It primarily serves small and midsize hospitals, clinics, and laboratories in out-patient care. The company was founded in 1956 and is headquartered in Stockholm, Sweden.

Founded in 1956

boule diagnostics internatio (BOUL) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr1.5M
Compensation as of Fiscal Year 2013.

boule diagnostics internatio (BOUL) Key Developments

Boule Diagnostics AB Reports Audited Consolidated and Parent Company Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Boule Diagnostics AB reported audited consolidated and parent company earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, on consolidated basis, net sales were SEK 90.1 million against SEK 72.2 million last year. Operating profit was SEK 7.1 million against SEK 3.3 million last year. Profit before tax was SEK 6.9 million against SEK 2.8 million last year. Net profit was SEK 14.8 million or SEK 3.14 per share before and after dilution against net loss of SEK 1.9 million or SEK 0.41 per share before and after dilution last year. Cash flow from operating activities was SEK 12.2 million against SEK 2.6 million last year. Acquisition of tangible fixed assets was SEK 1.5 million against SEK 0.2 million last year. EBITDA was SEK 9.3 million against SEK 4.6 million last year. Return on equity was 9.2%. Although the increase in sales in the fourth quarter was primarily due to sound instrument sales, the USD exchange rate also had a positive impact on revenues. These good sales figures, combined with the cost and efficiency savings from the P20 productivity project that was launched during the year, resulted in an operating profit of SEK 7 million. Cash flow also improved in 2014, mostly due to the higher profit figures, but also due to less operating capital being tied up and less investment in intangible assets. For the year, on consolidated basis, net sales were SEK 306.7 million against SEK 276.8 million last year. Operating profit was SEK 26.6 million against operating loss of SEK 82.4 million last year. Profit before tax was SEK 24.9 million against loss before tax of SEK 84.2 million last year. Net profit was SEK 30.3 million or SEK 6.44 per share before and after dilution against net loss of SEK 70.1 million or SEK 14.90 per share before and after dilution last year. Cash flow from operating activities was SEK 31.0 million against SEK 20.7 million last year. Acquisition of tangible fixed assets was SEK 5.9 million against SEK 15.0 million last year. Return on equity was 20.4%. For the quarter, on parent company basis, net sales were SEK 2.2 million against SEK 2.4 million last year. Operating loss was SEK 5.8 million against SEK 3.0 million last year. Loss after financial items was SEK 5.8 million against SEK 3.0 million last year. Loss Profit before tax was SEK 4.9 million against loss before tax of SEK 3.0 million last year. Net profit was SEK 4.9 million against net loss of SEK 3.0 million last year. For the year, on parent company basis, net sales were SEK 16.1 million against SEK 9.8 million last year. Operating loss was SEK 10.6 million against SEK 12.7 million last year. Loss after financial items was SEK 10.7 million against SEK 12.7 million last year. Loss before tax was SEK 0.1 million against SEK 12.7 million last year. Net loss was SEK 0.1 million against net loss of SEK 12.7 million last year.

Boule Diagnostics AB to Report Fiscal Year 2014 Results on Feb 13, 2015

Boule Diagnostics AB announced that they will report fiscal year 2014 results on Feb 13, 2015

Boule Diagnostics AB Wins Strategic Instruments Procurement

Boule Diagnostics AB has won the procurement of instruments for blood cell counting in primary care in Östergötland. This contract was made by the County Council of Östergötland and includes 35 of Boules recently introduced generation of instruments; Swelab Alpha Plus. The installation will take place during the second quarter of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BOUL:SS kr83.50 SEK -4.25

BOUL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BOUL.
View Industry Companies
 

Industry Analysis

BOUL

Industry Average

Valuation BOUL Industry Range
Price/Earnings 11.8x
Price/Sales 1.2x
Price/Book 2.1x
Price/Cash Flow 11.8x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BOULE DIAGNOSTICS INTERNATIO, please visit www.boule.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.